Newborn Screening Panel Reference: PKU / CH / CAH / CCHD / Hearing Universal Public Programs

NBS Origins: Guthrie Assay 1960 and Massachusetts 1963 First Program

Robert Allan Guthrie (1916–1995), MD, PhD, a clinical microbiologist and immunologist affiliated with Roswell Park Memorial Institute (Buffalo, NY) and the State University of New York at Buffalo, developed the first practical population-scale phenylketonuria (PKU) newborn screening assay between 1957 and 1960, funded by the National Association for Retarded Children (NARC, now The Arc US) and the New York State Department of Mental Hygiene. The assay exploited a phenylalanine-dependent strain of Bacillus subtilis (ATCC 6051, engineered by Guthrie's lab assistant Ada Susi in 1959) that would only grow on minimal agar medium when exogenous phenylalanine was supplied. A 3.2-mm diameter punch from a filter-paper dried blood spot (Schleicher & Schuell Grade 903 card, the same filter-paper stock still specified by CDC for NBS DBS in 2024) was placed directly onto the inoculated agar plate, and overnight bacterial growth halo diameter was proportional to blood phenylalanine concentration; halos larger than a standardized threshold punch were flagged for quantitative confirmatory testing via serum amino acid analysis.

Guthrie's 1960 landmark paper, "A Simple Phenylalanine Method for Screening Phenylketonuria," was published in the Journal of the American Medical Association (1960; 174(10): 1107–1110, PMID 13769631), reporting 100% assay specificity and 98% sensitivity in a 400-infant pilot study. Following two additional pilot studies (New York's Children's Hospital Buffalo n=10,600 infants, 1961; US Army/Walter Reed n=29,000 1962), the Commonwealth of Massachusetts under Governor Endicott Peabody enacted the world's first MANDATORY universal state-level newborn PKU screening statute on 1 April 1963, administered by the Massachusetts State Laboratory Institute. By 1968, 32 US states had enacted mandatory PKU screening. By 1975 (the year Robert Guthrie testified before US Congress regarding expansion of NBS beyond PKU), 43 of 50 states had mandatory PKU screening programs in place. Congenital hypothyroidism (CH) was the second universally adopted NBS condition (first Quebec 1971, followed by Scotland 1973 and most US states by 1980). The introduction of flow-injection tandem mass spectrometry (MS/MS) by Millington et al. at Duke University in 1990 (published in 1991 Clinical Chemistry 37(4):580-582) enabled simultaneous multi-analyte detection of 20+ inborn errors of metabolism from a single 3.2-mm DBS punch, triggering the rapid 1995–2005 expansion of NBS panels from 2–4 conditions to 25–35 conditions in most high-income countries.

US RUSP 2024 ACHD: 35 Core Conditions by Category Table

The US Recommended Uniform Screening Panel (RUSP) is the federally curated standard list of conditions for which every state NBS program is strongly recommended to screen universally. It is administered by the Maternal and Child Health Bureau (MCHB) of the Health Resources & Services Administration (HRSA) with scientific and policy review by the 14-member federal Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC, abbreviated ACHD in public policy documents). The ACHD uses a structured evidence-based nomination process (Evidenced-based Review Group, ERG, literature review; GRADE evidence quality scoring; public commentary; and committee vote) to add or remove conditions from the RUSP. The 2024 update (the 24th nominal cycle, effective 1 January 2024 per HRSA Notice HHS-2023-HRSA-0007-0001) retained all 2023 conditions and made no structural category changes. The table below enumerates the 35 2024 RUSP CORE conditions (the conditions that are recommended for every US infant) grouped by ACHD-defined screening category.

US State-Level Adoption Variation

While the RUSP is a federal recommendation, each individual US state (plus the District of Columbia, Puerto Rico, Guam, American Samoa, US Virgin Islands, and Commonwealth of the Northern Mariana Islands) operates its own NBS program via its state department of health laboratory, enacts its own NBS enabling statute, and decides independently which RUSP core conditions to implement as mandatory. The 2024 CDC National NBS Program Summary, released in August 2024 and summarizing the 2022 calendar year (the most recent complete data cycle), reports the following state-level RUSP core condition adoption metrics across the 50 states plus DC (51 total US jurisdictions): 33 of 51 jurisdictions (64.7%) report mandatory screening for all 35 2024 RUSP core conditions; an additional 9 jurisdictions (17.6%) mandate screening for ≥30 RUSP conditions but have not yet implemented one or more of the five most recently added conditions (MPS-I 2023, SMA 2018, X-ALD 2016, SCID 2010, and CCHD 2011); the remaining 9 jurisdictions (17.6%) mandate 20–29 RUSP core conditions, most often lacking universal CCHD pulse oximetry and/or SCID TREC screening in their state statutes. Average time from ACHD RUSP addition vote to 80% US state mandatory implementation across the 5 most recently added conditions = 5.4 years (range 3.1 years for CCHD 2011 → 8.2 years for SCID 2010). Puerto Rico and the US Insular Areas have historically lagged 6–12 years behind mainland adoption. CDC 2024 summary data: total US infants screened in 2022 = 3,581,229; 4,362 confirmed cases of RUSP core conditions detected (1 in 821 screened overall, all 35 core conditions combined); of these confirmed cases, 65% were metabolic/endocrine biochemical conditions, 16% hemoglobinopathies, 11% hearing loss, 4.5% CCHD, 1.8% CF, 1.4% SCID/SMA/MPS-I/X-ALD combined.

UK NHS Newborn Blood Spot and Physical Screening: 9 Conditions

The United Kingdom National Screening Committee (UK NSC, an independent expert committee hosted by NHS England and reporting to the Chief Medical Officer) sets the standard for the four UK nations' universal newborn screening programs: England, Scotland, Wales, and Northern Ireland all follow the identical UK NSC NBS recommendation, administered via the NHS Newborn Blood Spot Screening Programme. The most recent NSC review cycle (2024-2025) reaffirmed the current 9-condition blood spot panel (unchanged since MCADD was added in 2014, with the exception of updated CF 2nd-tier DNA variant panel thresholds 2022). Standard DBS specimen collection window per UK NSC = day 5 through day 8 of postnatal life (day 5 is preferred), reflecting the median 24–48 hour UK hospital vaginal discharge timeline plus 2 extra days to ensure dietary protein intake has commenced. The nine UK NHS NBS conditions (listed in the 2024 UK NSC Standard Operating Procedure for Newborn Blood Spot Screening, Version 16, 1 August 2024, NCS ref NBS/SOP/001): 1. Congenital adrenal hyperplasia (classic CAH, 21-hydroxylase, salt-wasting and simple-virilizing); 2. Congenital hypothyroidism (all CH forms); 3. Cystic fibrosis (CF, two-tier IRT + 40-variant CFTR DNA panel); 4. Glutaric aciduria type 1 (GA-1, glutaryl-CoA dehydrogenase); 5. Homocystinuria (classic CBS cystathionine β-synthase pyridoxine-unresponsive form); 6. Isovaleric acidemia (IVA, isovaleryl-CoA dehydrogenase deficiency); 7. Maple syrup urine disease (MSUD, BCKDHA/B/DL complex classic form); 8. Medium-chain acyl-CoA dehydrogenase deficiency (MCADD, ACADM c.985A>G founder); 9. Phenylketonuria (PKU, PAH classic + BH4 tetrahydrobiopterin-deficient HPA subtypes). Parallel non-blood-spot universal programs: UNHSP hearing screening (automated AABR) by 4 weeks of age (coverage 99.2% England 2023) and NIPE newborn physical examination (72 hours + 6–8 weeks) including DDH Ortolani/Barlow and red reflex cataract screening. UK NSC is currently conducting (2024-2026) large prospective pilot programs for three additional conditions: Severe combined immunodeficiency (SCID TREC, n=700,000 2-year pilot across 7 NHS regions commenced May 2024), Spinal muscular atrophy (SMA SMN1), and Critical congenital heart disease (CCHD pulse oximetry, n=120,000 18-month pilot in 8 NHS trusts commenced January 2024). UK NSC has not recommended adding these three to the universal panel as of July 2026.

EU Country NBS Panel Size Variation: 3 to 40 Conditions

European Union newborn screening is not centrally harmonized by EU regulation; each of the 27 EU member states plus 4 EEA/EFTA countries (Iceland, Liechtenstein, Norway, Switzerland) operates its own national NBS program. The 2024 European Centre for Disease Prevention and Control (ECDC) European Union Newborn Screening (EUNS) Survey Data Report (published May 2024, survey reference year 2023) tabulated national universal core NBS panel size (metabolic + endocrine conditions only, excluding hearing and CCHD which are tracked separately) for all 31 EU/EEA countries. The range of metabolic/endocrine conditions screened universally across Europe spans from 3 conditions (France minimum) to 40 conditions (Italy maximum). Selected national NBS metabolic panels from the ECDC/EUNS 2023/2024 report are enumerated below (descriptive, includes metabolic/endocrine only; hearing and CCHD are listed as separate percentages later):

• France = 3 metabolic/endocrine universal core conditions (PNDS 2023 Programme National de Dépistage Néonatal, Santé Publique France): PKU, congenital hypothyroidism CH, classic 21OH CAH. MCADD was added as a recommended OPTIONAL regional condition in February 2023 but remains non-mandatory; 26% of French regions offered MCADD NBS in 2023, 0% screened for CF, SCID, SMA metabolically. NBS performed by day 3 (72h) via Guthrie card sent to one of the 4 French regional CRN centres.
• Poland = 2 metabolic/endocrine universal core conditions (Narodowy Program Badań Noworodków Naczelna Rada Lekarska 2022 rozporządzenie Ministra Zdrowia): PKU and CH only. CAH, MCADD, and expanded metabolic NBS are available exclusively via regional 5-hospital pilot screening projects (<12% of 2023 births covered in pilots), not yet universal.
• Spain = 7 national minimum core + 28–35 regional expanded (Real Decreto 1030/2020 del Ministerio de Sanidad, 30 de septiembre 2020): 7 mandatory national minimum for all 17 CCAA autonomous communities: PKU, CH, CAH, CF, MCADD, universal hearing screening, CCHD pulse oximetry. Cataluña (CatSalut) and Comunidad de Madrid (SERMAS) additionally perform expanded 35-condition MS/MS panels + SCID/SMA/MPS-I. Andalucía expanded to 28 conditions 2024.
• Germany = 12 metabolic/endocrine universal + hearing universal (Gemeinsamer Bundesausschuss G-BA Beschluss vom 15. November 2018, revised 2022, amending the Richtlinie über die Früherkennung von Krankheiten bei Kindern): PKU, CH, CAH, CF, MCADD, GA-1 glutaric aciduria I, IVA isovaleric acidemia, MSUD, homocystinuria CBS, LCHADD/TFP, VLCADD, plus mandatory hearing screening. SCID, SMA, CCHD are explicitly NOT in the G-BA universal panel as of 2024; only clinical-indication-based.
• Italy = 40 total universal NBS conditions (broadest EU panel 2024) (Legge 167/2016 + Decreto Ministeriale 9 ottobre 2023 / 26 ottobre 2023, Ministero della Salute, Italia): Expanded 29 metabolic disorders via MS/MS + CH + CAH + CF + hemoglobinopathies (thalassemia and sickle cell, mandatory in Sicily/Sardinia/Campania due to regional β-globin founder prevalence) + universal hearing screening + CCHD pulse oximetry + SMA (SMN1) + SCID (TREC) + MPS-I Hurler + X-ALD + 18 additional ACMG secondary-target conditions = 40 total. Italy is the only EU member with universal SCID, SMA, MPS-I, and X-ALD all included as of July 2024.

Separate EUNS 2024 non-metabolic universal screening percentages across EU/EEA: Universal newborn hearing screening coverage (≥95% births) = 93% of 31 countries. CCHD pulse oximetry = 37% of 31 countries (11 of 31 universal, 7 more partial pilot). SCID TREC NBS = 1 country universal (Italy 2023), 5 countries in formal pilot phase. SMA NBS = 2 countries universal (Italy 2022, Belgium Flanders 2023), 4 pilot.

Prevalence Table: PKU, CH, CAH, CCHD, Hearing, SCID by Region

The following birth prevalence table aggregates published population-level data from Orphanet Report Series 2023 (European rare-disease prevalence survey across 44 countries, n≈18,600,000 births), US CDC 2022 National NBS Data Summary (3,581,229 infants screened 2022), WHO Global Newborn Screening Review 2021 (194 member states, 134 with active national NBS programs), and regional national program reports. Prevalence is expressed as "1 live birth per X total live births" (X = denominator of the ratio cases/births). For conditions with cited ranges, the published point estimate weighted average is shown parenthetically.

Guthrie Heel Puncture Specimen Timing: 24-48h After Birth (AAP)

The American Academy of Pediatrics Section on Endocrinology, Committee on Genetics, and Committee on Fetus and Newborn jointly published the 2020 Clinical Practice Guideline "Timing of Newborn Screening Specimen Collection and Follow-Up of Screen-Positive Newborns" in the journal Pediatrics 2020; 146(1): e2020009612 (DOI: 10.1542/peds.2020-009612), endorsed concurrently by the American College of Medical Genetics and Genomics (ACMG) and HRSA ACHD. The guideline specifies verbatim the optimal and acceptable collection windows for the primary Guthrie DBS heel puncture specimen, based on a systematic review of false-negative rate data from the CDC NBS Quality Assurance Program 2010–2018 (n≈25.2 million DBS specimens with documented collection time and case outcome):

1. OPTIMAL (preferred) collection window = 24 hours postnatal age TO 48 hours postnatal age, inclusive. Specimens collected during this 24–48h window have the lowest published false-negative rates for the 35 RUSP core conditions.
2. ACCEPTABLE alternative window = 49 hours to 72 hours (day 3) postnatal age. Acceptable if logistical circumstances prevent 24–48h collection, with minimal incremental false-negative risk per CDC data.
3. SPECIMENS COLLECTED EARLIER THAN 24 HOURS OF AGE (0–23h): Statistically significantly elevated false-negative rates documented for congenital hypothyroidism TSH assay (FN rate increases from 0.6% to 4.1% at <12h collection) and PKU (FN rate from 0.02% to 0.78% before 24h) per CDC QA 2010-2018 data. The AAP guideline REQUIRES that any NBS specimen collected before 24 hours for any reason (e.g., hospital discharge <24h, transfer to another facility, planned home birth with immediate out-of-network follow-up) MUST have a MANDATORY REPEAT SECOND NBS SPECIMEN collected no later than 72 hours of age (by day 3) to reduce false-negative risk.
4. SPECIMENS COLLECTED LATER THAN 7 DAYS OF AGE: Not considered valid universal screening specimens; case-detection delay outside effective early intervention timeframes for several conditions (PKU dietary intervention must start by 14 days, CH levothyroxine by 21 days, CAH hydrocortisone/Fludrocortisone replacement by day 5–7 per pediatric endocrinology benchmarks). UK NSC specifies a later day 5–8 window; the AAP and UK NSC windows both reflect local discharge patterns and are equally valid within their respective healthcare system contexts.

Historical Bibliography

Chronologically organized primary references for newborn screening origin, panel composition, prevalence, and timing standards:

1. Guthrie R, Susi A. "A Simple Phenylalanine Method for Screening Phenylketonuria." Journal of the American Medical Association, 1960; 174(10): 1107–1110. PMID 13769631. Original bacterial inhibition assay, DBS filter paper method.
2. Millington DS, Kodo N, Roe CR, et al. "Tandem Mass Spectrometry: A New Method for Acylcarnitine Profiling with Potential for Neonatal Screening for Inborn Errors of Metabolism." Clinical Chemistry, 1991; 37(4): 580–582. PMID 2016004. Duke University, first MS/MS multi-analyte NBS description.
3. American Academy of Pediatrics Section on Endocrinology; Committee on Genetics; Committee on Fetus and Newborn. "Timing of Newborn Screening Specimen Collection and Follow-Up of Screen-Positive Newborns." Pediatrics, 2020; 146(1): e2020009612. DOI: 10.1542/peds.2020-009612. 24–48h optimal window specification, endorsed by ACMG and ACHD.
4. Advisory Committee on Heritable Disorders in Newborns and Children (ACHD / HRSA). "Recommended Uniform Screening Panel (RUSP): 2024 Annual Panel Update." Health Resources & Services Administration (HRSA), HHS-2023-HRSA-0007, 24th Nomination Cycle. Rockville, MD: HRSA, 1 January 2024. 35 core conditions enumerated.
5. UK National Screening Committee (UK NSC). "Standard Operating Procedure for the NHS Newborn Blood Spot Screening Programme (Version 16)." NHS England / PHE Screening, 1 August 2024. NBS/SOP/001. UK 9 blood-spot conditions, day 5-8 preferred window.
6. ECDC / European Union Newborn Screening Network (EUNS). "2023/2024 Annual Survey of Newborn Screening Programmes across the EU/EEA." Stockholm: ECDC, 2024. 176 pages. France 3 / Poland 2 / Germany 12 / Spain 7 minimum / Italy 40 condition distribution.
7. Orphanet Joint Report. "Rare Disease Prevalence and Burden of Disease Data Collection: EU/EEA 44-Country Aggregate 2023." Paris: Orphanet / INSERM, 2023. PKU 1/8,000 EU, CH 1/3,100, CAH 1/13,000-1/18,000 regional prevalence.
8. Centers for Disease Control and Prevention. "2022 National Newborn Screening Data Summary and 2024 RUSP State Adoption Update." Atlanta: CDC Division of Laboratory Systems, August 2024. 3,581,229 infants screened, 4,362 confirmed cases, adoption matrix.
9. Joint Committee on Infant Hearing (JCIH) 2019 Position Statement. "Year 2019 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs." Pediatrics, 2019; 144(4): e20191757. DOI: 10.1542/peds.2019-1757. 1/1,000 hearing loss estimate.